Clinical impact MicrobeDx offers rapid phenotypic antimicrobial susceptibility testing that delivers actionable results within three hours of patient encounter, enabling clinicians to select the first-dose antibiotic more accurately and potentially reduce unnecessary antibiotic use.

Targeted outreach The company operates with a small team and serves clinical microbiology settings; sales efforts should focus on hospital laboratories and regional clinics seeking rapid AST solutions to combat antibiotic resistance and improve patient outcomes.

Differentiation edge Emphasize the phenotypic AST approach that does not rely on an expanding target gene list, highlighting resilience to resistance evolution and a broad applicability across bacterial pathogens.

Growth opportunity With revenue in the low-to-mid single digits and nearing $1M-$10M range, there is room to scale by targeting mid-sized hospitals and outpatient networks that could benefit from rapid diagnostic guidance and antibiotic stewardship.

Digital readiness Leverage their tech stack and readiness for digital engagement (PWA, Bootstrap, Open Graph) to deploy SDR outreach, product demos, and online trials, accelerating adoption in clinical settings.